A Novel-Defined Necroptosis-Related miRNA Signature for Forecasting the Prognosis of Low-Grade Glioma.

Abstract

Background Increasing evidence has shown that necroptosis has enormous significance in the generation and deterioration of cancer, and miRNA molecular markers involved in necroptosis in low-grade gliomas (LGGs) have not been thoroughly reported. Methods Using the miRNA data of 512 samples from The Cancer Genome Atlas (TCGA), 689 miRNAs from LGG samples were split into high immunity score and low immunity score groups for analysis. The differential miRNAs related to necroptosis were analyzed by univariate Cox regression analysis. On the basis of the outcome of univariate Cox regression analysis, miRNAs with significant differences were selected to construct a multivariate Cox regression model and calculate the risk score. Then, we evaluated whether the risk score could be used as an unaided prognostic factor. Results Overall, six differential miRNAs were identified (hsa-miR-148a-3p, hsa-miR-141-3p, hsa-miR-223-3p, hsa-miR-7-5p, hsa-miR-500a-3p, and hsa-miR-200a-5p). Univariate and multivariate Cox regression analyses were performed, and the c index was 0.71. Then, by mixing the risk score with clinicopathological factors, univariate Cox regression (HR: 2.7146, 95% CI: 1.8402−4.0044, P < 0.0001) and multivariate Cox regression analyses (HR: 2.3280, 95% CI: 1.5692−3.4536, P < 0.001) were performed. The data suggested that the risk score is an unaided prognostic indicator, which is markedly related with the overall survival time of LGG sufferers. Thus, a lower risk score is correlated with better prediction of LGG. Conclusion In order to achieve the ultimate goal of improving the living conditions of patients, we established prognostic risk model using 6 miRNAs related to necroptosis, which has the ability to predict the prognosis of LGG. It is possible to further enrich the therapeutic targets for LGG and provide clinical guidance for the treatment of LGG in the future.